News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Furiex Pharmaceuticals, Inc. (FURX) Says Johnson & Johnson (JNJ) Returns Sexual Dysfunction Drug Rights



5/15/2012 7:27:18 AM

Furiex Pharmaceuticals Inc said its partner Johnson & Johnson returned the worldwide rights for its oral drug to treat premature ejaculation. Furiex said it has licensed the rights of the drug to European pharmaceutical company Menarini in Europe, most of Asia, Africa, Latin America and the Middle East for $15 million in cash. Furiex will also get up to $60 million if the drug clears certain regulatory and sales milestones. The drug, Priligy, which is still not approved in the United States, is marketed by J&J unit Janssen Pharmaceutica in 15 countries in Europe, Asia and Latin America.

Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES